Shares of Harrow, Inc. (NASDAQ:HROW - Get Free Report) have earned an average recommendation of "Hold" from the nine ratings firms that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $66.20.
HROW has been the subject of a number of analyst reports. Weiss Ratings upgraded shares of Harrow from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, November 13th. Leerink Partners initiated coverage on shares of Harrow in a research report on Wednesday, September 9th. They issued an "outperform" rating and a $45.00 target price for the company. Wall Street Zen upgraded shares of Harrow from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. Zacks Research lowered shares of Harrow from a "hold" rating to a "strong sell" rating in a research note on Tuesday, November 3rd. Finally, BTIG Research restated a "buy" rating and set a $63.00 price target on shares of Harrow in a report on Wednesday, November 11th.
View Our Latest Report on HROW
Harrow Price Performance
HROW opened at $32.16 on Thursday. The stock has a fifty day moving average price of $30.31 and a 200 day moving average price of $37.35. The company has a current ratio of 2.29, a quick ratio of 2.12 and a debt-to-equity ratio of 10.15. Harrow has a 1 year low of $25.76 and a 1 year high of $54.85. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -41.23 and a beta of 0.18.
Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.19 by $0.06. Harrow had a negative return on equity of 69.81% and a negative net margin of 9.39%. The business had revenue of $99.30 million during the quarter, compared to analysts' expectations of $98.59 million. Analysts forecast that Harrow will post -0.50 EPS for the current fiscal year.
Institutional Investors Weigh In On Harrow
A number of large investors have recently bought and sold shares of the business. KBC Group NV bought a new position in Harrow during the first quarter valued at about $31,000. Sterling Capital Management LLC lifted its position in shares of Harrow by 836.8% in the third quarter. Sterling Capital Management LLC now owns 1,068 shares of the company's stock worth $33,000 after buying an additional 954 shares during the last quarter. Toronto Dominion Bank acquired a new stake in shares of Harrow in the third quarter worth about $46,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Harrow during the 3rd quarter worth about $59,000. Finally, First Bancorp Inc ME bought a new stake in shares of Harrow during the 2nd quarter worth about $64,000. 72.76% of the stock is currently owned by institutional investors.
About Harrow
(
Get Free Report)
Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.